RENX — Renalytix Cashflow Statement
0.000.00%
Last trade - 00:00- £29.50m
- £32.95m
- $3.00m
Annual cashflow statement for Renalytix, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -35.8 | -49.6 | -46.2 | -45.5 | -21.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 5.7 | 1.25 | 4.87 | 16.4 | 7.2 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.36 | 0.016 | 6.18 | -3.21 | -3.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -24.6 | -45.7 | -32.7 | -29.8 | -17.9 |
| Capital Expenditures | -1.63 | -0.694 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.889 | — | 0 | 0.117 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.741 | -0.694 | 0 | 0.117 | 0 |
| Financing Cash Flow Items | 0.111 | -1.51 | -0.16 | -0.156 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 77.2 | 25.5 | 15.1 | 10.1 | 16 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 51.9 | -23.8 | -16.7 | -20 | -1.1 |